| abstract |
Antibody formulations comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid are described. The disclosed formulations have improved stability, reduced aggregate formation, in which they may delay degradation of the anti-α4β7 antibody or exhibit any combination thereof. The present invention further provides safe dosing regimens of these antibody formulations that are easy to follow and result in therapeutically effective amounts of anti-α4β7 antibodies in vivo. |